Medication info
Polminlina Sustained Release Tablets 2.5/750mg (Linagliptin, Metformin Hydrochloride)

Polminlina Sustained Release Tablets 2.5/750mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Micronized›2.5mg / 1 tabletMetformin Hydrochloride›750mg / 1 tablet
Manufacturer / importer
NOKSIBJA Co., Ltd.
Appearance
White oval sustained-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202500884 · Approved 2025.04.14 · Insurance code 643606860

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and extended-release metformin hydrochloride 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, increase the metformin hydrochloride dose gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Patients taking this medicine as 5/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 2.5/750 mg or 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000 mg. The metformin hydrochloride dose may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine comprising a total daily dose of linagliptin 5 mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, use the doses of linagliptin and extended-release metformin hydrochloride the patient was previously taking. Renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73m2]. In patients with moderate renal impairment (CKD stage 3A) with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, discontinue this medicine immediately.

Ingredients

Manufacturer
NOKSIBJA Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood glucose control for patients with type 2 diabetes through the combination of linagliptin and metformin. It can be effectively managed when administered alongside dietary regulation and exercise therapy. This helps improve the blood glucose levels in patients with type 2 diabetes and contributes to the prevention of complications.

How to take

Adult dose

For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5 mg and extended-release metformin hydrochloride 2000 mg. Take this medicine once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, increase the metformin hydrochloride dose gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Patients taking this medicine as 5/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 2.5/750 mg or 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000 mg. The metformin hydrochloride dose may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine comprising a total daily dose of linagliptin 5 mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, use the doses of linagliptin and extended-release metformin hydrochloride the patient was previously taking. Renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is required in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73m2]. In patients with moderate renal impairment (CKD stage 3A) with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, discontinue this medicine immediately.

Precautions

This medication helps control blood glucose levels. However, it can rarely cause a dangerous condition called lactic acidosis, so caution is required. Patients who are allergic to this drug or have type 1 diabetes, significantly decreased kidney function, or severe liver disease should not use this medication. Additionally, patients experiencing acute conditions that may affect kidney function, such as dehydration, severe infection, or acute myocardial infarction, may be at risk for using this medication. There is a risk of hypoglycemia, thus caution is especially needed when used with other hypoglycemic agents such as insulin or sulfonylureas. During treatment, kidney function should be regularly monitored, and if kidney function deteriorates, the medication should be discontinued. Rare side effects such as acute pancreatitis or skin blistering resembling bullous pemphigoid have been reported, so if severe abdominal pain or skin abnormalities occur, notify a physician immediately. This medication can be taken regardless of meals, but do not crush, chew, or break the tablet; it should be swallowed whole, and the tablet coat may appear in the stool, which should not be a cause for concern. It is preferable not to use this medication during pregnancy or while breastfeeding, and elderly patients may require dosage adjustments and monitoring of kidney function due to common decline in kidney function. Additionally, it is advisable to avoid alcohol consumption while taking this medication, and inform the physician or pharmacist of any other medications being taken as they may interact. In cases of overdose, the risk of lactic acidosis increases, necessitating immediate medical treatment. Lastly, this medication should be kept out of reach of children and stored away from moisture.

Side effects

Severe lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity reactions, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test, hypoglycemic episode, taste disturbance, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, pemphigus-like eruptions, joint pain with severe and disability, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's-type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, pneumonia, hypercholesterolemia, headache, drowsiness, chest discomfort, asthenia, epistaxis, oropharyngeal pain, vocal cord dysfunction, allergic rhinitis, exertional dyspnea, productive cough, rhinitis, pulmonary mass, joint pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, hypochromia, hyperkalemia, increased serum creatinine, increased serum creatine phosphokinase activity, increased ALT, male pattern baldness, hyperhidrosis, dermatitis, anxiety, mood disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hearing loss, erectile dysfunction, thyroid goiter, confusion state, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it is recommended to store it at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the drug's effectiveness over time.

Appearance and packaging

Appearance

White oval sustained-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.